Floatz logo

Trastuzumab Emtansine

Oligometastatic Disease

N.N. Petrov National Medical Research Center of Oncologyantibody_drug_conjugateN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Oligometastatic Disease cohort.

Asset / SponsorPhaseRating
Eovist
University of Colorado, Denver
Phase 4B
GADOBENATE DIMEGLUMINE
University of Colorado, Denver
Phase 4B
FLUOROURACILUM
UMC Utrecht
Phase 2CCC
Eloxatin
University of Cologne
Phase 2CCC
Tislelizumab
Peking University Cancer Hospital & Institute
Phase 2CCC

View all 20 →

Same molecule, other indications

Trastuzumab Emtansine is also rated in:

Breast Inflammatory CarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →